Advancing vaccine adjuvant research for tuberculosis

Closed Solicitation Posted

This opportunity was awarded. See the award notice from .

Solicitation number
BAA-DAIT-75N93021R00008
Agency
Responses due
Set-aside
No set-aside

Opportunity facts

Place of performance
United States

Notice details come from SAM.gov. Updated .

About this opportunity

The National Institute of Allergy and Infectious Diseases seeks to advance vaccine adjuvant research for tuberculosis through the procurement of three distinct Mycobacterium tuberculosis immunogens formulated with three different adjuvants representing various categories. Proposals must establish immunological profiles of the adjuvants and identify promising adjuvant-immunogen candidates for clinical development. Technical and cost factors will be evaluated with proposals due by August 10, 2021. Amendments clarify that nucleic acid vaccines and lipid nanoparticles used with two other adjuvants are within scope.

No set-aside is designated with research to be conducted domestically. Potential incumbents were not identified and budget details not provided. Proposals must include three distinct adjuvants formulated with or without modulators to be tested alongside immunogens over the contract period to facilitate adjuvant-vaccine optimization for tuberculosis vaccines.

Notice text

Solicitation for BAA-DAIT-75N93021R00008 entitled, "Advancing Vaccine Adjuvant Research for Tuberculosis (TB)"

Files

File Type Posted
Amendment 2.pdf PDF
Amendment 1.pdf PDF
BAA-DAIT-75N93021R00008 Solicitation.pdf PDF

Notice history

Notice Type Posted
Advancing vaccine adjuvant research for tuberculosis Award Award Notice
This notice Latest solicitation Solicitation
Advancing vaccine adjuvant research for tuberculosis Original Pre-Solicitation

On GovTribe

Work this opportunity

  • Track it in your pipeline
  • Find teaming partners
  • Similar opportunities
  • Ask GovTribe AI about this opportunity

GovTribe for Federal Contractors